Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment
Pediatric Blood & Cancer · 2026-04 · 73 (4)
DOI: 10.1002/1545-5017.70167 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Blood & Cancer, online erschienen am 25.02.2026. Verfasst von Anne Ravix und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerlan…. Hauptthemen laut MEDLINE: Mercaptopurine, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Thioguanine, Antimetabolites, Antineoplastic. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer. The pro‐drug 6‐mercaptopurine (6‐MP), essential during maintenance, is converted into active 6‐thioguanine (6‐TGN) and toxic 6‐methylmercaptopurine (6‐MMP) metabolites, resulting in marked variability in efficacy and toxicity. 6‐MP therapy is further limited by poor adherence, variable absorption, and complex metabolism. Allopurinol is sometimes used to correct skewed metabolism, though its precise clinical role remains unclear.
Methods
This study aimed to develop population pharmacokinetic (popPK)‐based strategies to optimize 6‐MP dosing in children and improve therapeutic outcomes. A popPK model was developed using 6‐MMP and 6‐TGN concentrations from the pediatric oncology cohort. Model‐based simulations in 1000 virtual patients were performed to explore optimized dosing strategies, with and without allopurinol, aiming to reach the therapeutic target (6‐MMP
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Centre for Research and Innovation in Clinical Pharmaceutical Sciences, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- Division of Pediatrics, Department of Woman-Mother-Child, Pediatric Hematology-Oncology Unit, University Hospital of Lausanne and University of Lausanne, Lausanne, Switzerland.
- Service and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
- School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland.
- Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, University of Lausanne, Geneva, Switzerland.
ORCID-Profile: Anne Ravix, Francesco Ceppi
Zitieren
APA
Ravix, A., Maillat, A., Choong, E., Csajka, C., Guidi, M., & Ceppi, F. (2026). Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment. Pediatric Blood & Cancer, 73(4). https://doi.org/10.1002/1545-5017.70167
Vancouver
Ravix A, Maillat A, Choong E, Csajka C, Guidi M, Ceppi F. Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment. Pediatric Blood & Cancer. 2026;73(4). doi:10.1002/1545-5017.70167
BibTeX
@article{Ravix2026,
author = {Ravix, Anne and Maillat, Anaïs and Choong, Eva and Csajka, Chantal and Guidi, Monia and Ceppi, Francesco},
title = {Model‐Based Strategy for 6‐Mercaptopurine Treatment in Acute Lymphoblastic Leukemia Maintenance Phase: Prediction of 6‐TGN and 6‐MMP Concentrations to Optimize Treatment},
journal = {Pediatric Blood & Cancer},
year = {2026},
volume = {73},
number = {4},
doi = {10.1002/1545-5017.70167}
}
EUVIMED